Comparative Pharmacology
Head-to-head clinical analysis: NINTEDANIB ESYLATE versus OFEV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NINTEDANIB ESYLATE versus OFEV.
NINTEDANIB ESYLATE vs OFEV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nintedanib esylate is a tyrosine kinase inhibitor that binds competitively to the ATP-binding pocket of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α, PDGFR-β), and fibroblast growth factor receptors (FGFR-1, FGFR-2, FGFR-3). This inhibition blocks downstream signaling pathways involved in angiogenesis and fibrosis.
Nintedanib is a tyrosine kinase inhibitor that blocks the activity of fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR), thereby inhibiting fibroblast proliferation, migration, and transformation, and reducing extracellular matrix deposition.
150 mg orally twice daily, 12 hours apart, taken with food.
150 mg orally twice daily, taken with food.
None Documented
None Documented
Terminal elimination half-life is approximately 10 hours in patients with IPF; steady state reached within 7 days.
Terminal elimination half-life is approximately 38 hours (range 30–48 hours) at steady state, supporting once-daily dosing.
Biliary/fecal: >90% (unchanged and metabolites); Renal: <1%
Primarily biliary/fecal (~93.4% of total radioactivity recovered in feces), renal excretion is minor (~0.6% unchanged in urine).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor